Advertisement|Remove ads.

Shares of Immunic, Inc (IMUX) gained around 6% in pre-market trading on Wednesday after the company said it had regained compliance with Nasdaq’s listing rules on March 26.
The firm regained compliance after the stock closed at or above $1 for at least 20 consecutive business days. The update removes concerns about a potential delisting from the Nasdaq Capital Market.
On Tuesday, the company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board of directors.
Get updates to this developing story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.